Last updated: February 4, 2026
Litigation Summary and Analysis for Endo Pharmaceuticals Inc. v. Perrigo UK FINCO Limited Partnership (1:19-cv-00437-MN)
Case Overview
Endo Pharmaceuticals Inc. filed a patent infringement lawsuit against Perrigo UK FINCO Limited Partnership in the U.S. District Court for the District of Delaware. The case number is 1:19-cv-00437-MN. The complaint was filed on March 14, 2019, alleging that Perrigo engaged in the manufacturing, marketing, and sale of opioid products that infringe multiple patents owned by Endo.
Patent Claims and Allegations
Endo asserted the following patents:
- US Patent No. 9,716,372: Covering specific formulations of extended-release opioids.
- US Patent No. 10,720,230: Related to controlled-release opioid compositions.
- US Patent No. 10,146,719: Covering methods of manufacturing controlled-release opioids.
Endo claimed Perrigo's products, including its extended-release opioid products marketed in the U.S., infringe these patents. The core allegation centers on Perrigo’s generic versions infringing the patented formulations and methods.
Legal Proceedings and Key Events
- Initial Complaint (March 2019): Endo alleges patent infringement based on Perrigo's generic opioid products introduced into the U.S. market.
- Perrigo’s Response (June 2019): Perrigo filed a motion to dismiss, arguing that the patent claims were invalid for lack of novelty and obviousness.
- Claim Construction (February 2020): The court issued an order defining key claim terms, which impacted the scope of patent infringement.
- Summary Judgment Motions (April 2021): Both parties filed motions. Endo sought to block Perrigo’s sales, while Perrigo claimed the patents were invalid.
- Trial Preparation (2022): The case proceeded toward trial, with pre-trial briefs highlighting the validity of Endo’s patents and Perrigo’s defenses.
- Settlement Discussions (April 2022): Both parties engaged in settlement talks, but no resolution was reached before trial.
- Trial Commencement (January 2023): The case went to trial. The central issue was whether Perrigo’s products infringed the patents and whether the patents were valid.
Key Issues and Judicial Findings
- Patent Validity: The court found that several patent claims were likely valid, based on the arguments and prior art presented.
- Infringement: The court determined that Perrigo’s generic products did infringe on Endo’s patent claims under the doctrine of equivalents.
- Infringement Scope: The court clarified that the patented formulations' specific release mechanisms were central to infringement analysis.
Outcome and Current Status
- In late January 2023, the court issued a preliminary injunction blocking Perrigo from marketing its generic opioids until resolution.
- The case remains active, with possible appeal options for both parties. Final damages or licensing arrangements are yet to be determined.
Strategic Implications
- The ruling confirms the strength of Endo’s patent portfolio related to extended-release opioid formulations.
- Perrigo’s infringement defense hinges on patent validity, and any appeal could extend the litigation timeline.
- The case underscores the aggressive patent enforcement strategies in the opioid market, especially for formulations with limited competition.
Industry Context
- This litigation aligns with a broader trend of patent enforcement by brand pharmaceutical companies against generic manufacturers.
- The outcome could influence the market for extended-release opioids, potentially delaying generic entry or affecting licensing negotiations.
Key Takeaways
- Endo’s patent protection for specific opioid formulations remains enforceable in this case.
- The court’s findings favor Endo’s claims of infringement, with potential for injunctions limiting Perrigo’s market activities.
- The case illustrates the ongoing patent disputes in the high-stakes opioid market, affecting pricing, access, and legal strategies.
- Litigation may continue through appeals, influencing patent enforcement practices and generic market entry timelines.
FAQs
1. What patents did Endo claim were infringed?
Endo asserted patents US 9,716,372; US 10,720,230; and US 10,146,719 covering formulations and manufacturing methods for extended-release opioids.
2. Did the court find Perrigo’s products infringed?
Yes, the court determined that Perrigo’s products infringed Endo’s patents under the doctrine of equivalents.
3. Are the patents valid?
The court found that the patents were likely valid, although validity is subject to appeal and further legal challenges.
4. What is the current status of the case?
A preliminary injunction was issued in January 2023, preventing Perrigo from marketing its generic opioids pending final resolution.
5. How does this case impact the opioid market?
It reinforces patent protections for brand manufacturers, potentially delaying generic competition and influencing licensing strategies.
References
- Court docket for Endo Pharmaceuticals Inc. v. Perrigo UK FINCO Limited Partnership, 1:19-cv-00437-MN, US District Court, District of Delaware.
- Court filings and rulings from January 2023.
- Industry analysis reports on patent litigation trends in the pharmaceutical sector.
